J.P. Morgan Healthcare Conference 2026

Takeaways from the 2026 J.P. Morgan Healthcare Conference, noting that despite a recent pullback in healthcare stocks, the prospects for innovation and dealmaking appear as strong as ever. The conference came on the heels of a significant decline in healthcare stocks, but we saw no signs the pace of medical innovation was slowing. On the contrary, new mergers and acquisitions were announced and firms reported significant progress in pipeline development and strong product launches. We came away from the conference believing today’s valuations do not adequately reflect the sector’s growth potential, creating an opportunity for long-term investors.